Skip to main content

Table 4 The improvement of BCVA and CST in patients using Ranibizumab and Aflibercept according to age

From: Effect of age on response to anti-VEGF agents in patients with center involving diabetic macular edema in a tertiary hospital

 

Age

 < 60

 > 60

Post–pre-BCVA*

Post–pre-CST*

Post–pre-BCVA

Post–pre-CST

Mean

Mean

Mean

Mean

Injection type

    

 Ranibizumab

19.13

 − 228.13

4.18

 − 100.29

 Aflibercept

4.26

 − 117.21

5.70

 − 91.40

  1. *BCVA, best-corrected visual acuity, CST, central subfield thickness